Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,238 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Not yet recruiting Phase 4 Interventional

Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess

NCT07704359
View directory record Official record
Conditions
Perianal Abscess, Anal Fistula
Interventions
Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

NCT07209462
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
13 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Irvine, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

NCT07547761
View directory record Official record
Conditions
Body Odor
Interventions
NOBO Aqueous Deodorant, Placebo Aqueous Deodorant
Other
Lead sponsor
Kingdom
Industry
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Withdrawn Phase 4 Interventional

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

NCT03481894
View directory record Official record
Conditions
Malnutrition
Interventions
Kabiven®, Compounded standard parenteral nutrition
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 10:45 PM EDT
Active, not recruiting Phase 3 Interventional

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Iltamiocel, Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
La Jolla, California • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 28, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea

NCT00672737
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Remifentanil, Cold pain threshold and tolerance, Heat pain threshold and tolerance, Polysomnography
Drug · Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 28, 2026, 10:45 PM EDT
Not listed Phase 2 Interventional

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

NCT04822961
View directory record Official record
Conditions
mCRPC
Interventions
Placebo, Senaparib
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

NCT00891683
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Chronic Pain
Interventions
AEG33773 oral dosing
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Santa Monica, California • Cincinnatti, Ohio • Kettering, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2010 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

NCT01887678
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Traumeel® / Zeel® Injectable Solution, Placebo
Drug
Lead sponsor
Biologische Heilmittel Heel GmbH
Industry
Eligibility
45 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 28, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 28, 2026, 10:45 PM EDT
Active, not recruiting Not applicable Interventional

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions
FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

NCT02013050
View directory record Official record
Conditions
Oral Mucositis
Interventions
SGX942, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
28
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Terminated Not applicable Interventional Results available

Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

NCT05165108
View directory record Official record
Conditions
Crohn Disease
Interventions
Vagal Nerve Stimulator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes Study of MTM in a Medicare ACO

NCT02875925
View directory record Official record
Conditions
Pain, Hypoglycemia
Interventions
MTM
Other
Lead sponsor
HealthEast Care System
Other
Eligibility
66 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 28, 2026, 10:45 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers

NCT05657782
View directory record Official record
Conditions
Cholera, Cholera Vaccine Toxicity
Interventions
PanChol
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 28, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

What is the Effect of Increased Consumption of Fruit Juice on Exercise Capacity and Inflammatory Biomarkers?

NCT07862049
View directory record Official record
Conditions
Inflammation, C-reactive Protein, Exercise Capacity
Interventions
Active Fruit Juice Intervention, Control Fruit Juice Intervention
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation

NCT00523978
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Arctic Front® Cryoablation Catheter, Flecainide or Sotalol or Propafenone
Device · Drug
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 28, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

NCT01754818
View directory record Official record
Conditions
Healthy
Interventions
Bendavia 10mg, Bendavia 50mg, Bendavia 100mg, Placebo
Drug
Lead sponsor
Mighty Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 28, 2026, 10:45 PM EDT